Dear Doctor:
Clinical research gives many patients the possibility to participate in a study in which they are offered an effective alternative for their pathologies.
In the event that you refer a patient to our site, we will maintain regular and fluid contact to keep you informed about your patient from the moment of evaluation.
Phase III Study
The objective of this study is to determine the efficacy and safety of GSK3196165 (otilimab) in combination with methotrexate (MTX) for the treatment of adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to MTX. Otilimab (subcutaneously once weekly) is compared to tofacitinib (5 mg twice daily), a Janus kinase inhibitor (JAK) that is approved for the treatment of adults with moderately to severely active RA.
The efficacy and safety of GSK3196165 (otilimab) are evaluated in comparison with placebo and with tofacitinib.
Research Product: GSK3196165 (otilimab)
Otilimab is a monoclonal antibody that specifically binds to human GM-CSF and prevents its interaction with its receptor. GM-CSF is a pro-inflammatory cytokine that favors synovial inflammation in RA, since an increase in GM-CSF levels was observed in the synovial fluid of patients with RA and its receptor is expressed in synovial tissue. Elimination or neutralization of GM-CSF improves joint pain, function, and histological structure in patients with RA.
This study is aimed at patients with moderately to severely active RA, unresponsive to methotrexate.
Phase III Study
The objective of this study is to determine the efficacy and safety of GSK3196165, in combination with conventional synthetic disease-modifying antirheumatic drugs (ESCMAR), for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had a Inadequate response to biological DMARDs (b-DMARDs) and / or Janus kinase inhibitors (JAK). Two doses of GSK3196165 will be compared with sarilumab (200 mg subcutaneously every two weeks), an IL-6 inhibitor that is approved in many countries for the treatment of adults with moderately to severely active RA who have had an inadequate response. to b-DMARDs and / or JAK inhibitors.
Research Product: GSK3196165 (otilimab)
Otilimab is a monoclonal antibody that specifically binds to human GM-CSF and prevents its interaction with its receptor. GM-CSF is a pro-inflammatory cytokine that favors synovial inflammation in RA, since an increase in GM-CSF levels was observed in the synovial fluid of patients with RA and its receptor is expressed in synovial tissue. Elimination or neutralization of GM-CSF improves joint pain, function, and histological structure in patients with RA.
Phase III Study
The efficacy of dupilumab 300 mg every 2 weeks is evaluated. in patients with moderate or severe COPD.
Research Product: dupilumab
Dupilumab is a systemic targeted immunomodulatory agent that inhibits the Th2 pathway. It is a fully human monoclonal antibody (mAb) that targets the alpha subunit of the interleukin 4 receptor (IL-4Rα), a component of type I and type II IL-4 receptors, which mediate signaling by the IL-4 (both receptors) and by IL-13 (type II receptor).
Inclusion criteria
Phase III Study
The aim of the study is to measure the effect of treatment with estetrol 15 mg or 20 mg compared to placebo on the frequency and severity of moderate to severe vasomotor symptoms in postmenopausal women.
Research Product: estetrol
Inclusion criteria
Postmenopausal women ≥40 to ≤65 years of age with associated vasomotor symptoms (eg, hot flashes).
Phase III-IV Study
To compare the efficacy of fluticasone furoate / vilanterol once daily with fluticasone furoate once daily in participants with asthma.
Patients between 5 and 11 years
Diagnosis of asthma older than six months
Prebronchodilator FEV between 50 and 90%
Treatment for stable asthma
Phase III Study
Objetivo: To evaluate the efficacy and safety of CUSA-081 (Reteplase) vs Alteplase vs placebo in the treatment of CVAD (Central Catheters) dysfunction
Patients with obstructed CAVD with no more than 48 hours from the detection of the obstruction.
It cannot be CVAD used for hemodialysis.
You cannot have a catheter infection.
You cannot have bleeding disorders
You cannot be using blood thinners
Phase III Study
Mepolizumab as add-on treatment in patients with COPD characterized by frequent exacerbations and elevated eosinophil levels.
Research Product: mepolizumab
Mepolizumab is a monoclonal antibody that inhibits the ability of IL-5. It is administered subcutaneously once a month.
Inclusion criteria
For more information contact
Professional Relationships
